Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin + anlotinib vs epirubicin + ifosfamide for unresectable advanced or metastatic soft tissue sarcoma
ChiCTR2500113449Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Epirubicin plus anlotinib with Epirubicin plus ifosfamide (2 arms). Primary endpoint: Median progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
epirubicinanlotinibifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2500113449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113449.